Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketamine prolonged release oral - Ketabon

Next Previous
Drug Profile

Ketamine prolonged release oral - Ketabon

Alternative Names: KET-01; Ketamine hydrochloride prolonged-release tablets; Ketamine PR tablets

Latest Information Update: 18 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Develco Pharma Schweiz
  • Developer Develco Pharma Schweiz; Ketabon
  • Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Depressive disorders
  • Discontinued Neuropathic pain

Most Recent Events

  • 14 Aug 2023 Efficacy and adverse events data from a phase-II KET01-02 trial in Depressive disorders released by Ketabon (PO)
  • 05 May 2023 Ketabon completes phase-II KET01-02 trial in Depressive disorders in Germany, Poland, and the Czech Republic (PO) (EudraCT2021-004927-34)
  • 25 Oct 2022 Discontinued - Phase-II for Neuropathic pain in Germany (PO) (HMNC Brain Health pipeline, October 2022).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top